Professional
Added to YB: 2024-06-26
Pitch date: 2024-06-18
QGEN [neutral]
Qiagen N.V.
-15.78%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Market Cap
$6.8B
Pitch Price
$41.43
Price Target
52.00 (+49%)
Dividend
7.37%
EV/EBITDA
10.21
P/E
16.86
EV/Sales
3.71
Sector
Life Sciences Tools and Services
Category
growth
Show full summary:
Qiagen N.V.: Qiagen Still Pushing for Higher Growth Than Its End Markets
QGEN: Aims for mid-single digit rev growth, 10% EPS CAGR 2024-28. $52 PT. Strong in sample prep (34% sales), TB test (20%). Expanding in infectious diseases, oncology. Risks: tech disruption, product concentration. No moat but strong position. Med uncertainty. Standard capital allocation. Balance sheet <1x leveraged.
Read full article (7 min)